CAMBRIDGE, Mass. — Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its Helicon™ peptide platform to drug historically undruggable targets, today announced preliminary clinical and preclinical data at the 11th Biennial Meeting of the International Society for Gastrointestinal Hereditary Tumours (InSiGHT)...

MINNEAPOLIS, Minn. — DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that it has received a No Objection Letter (NOL) from Health Canada for its Clinical Trial Application to evaluate DM199 in...

ALBANY, N.Y. & SHANGHAI, China — Drug Farm today announced that the U.S. Food and Drug Administration (U.S. Food and Drug Administration, FDA) has accepted DF-003, the company’s investigational therapy for ROSAH syndrome, into the FDA Rare Disease Evidence Principles Process (RDEP). The RDEP is an FDA initiative designed to...